High-risk human papillomaviruses (HPV) induce cervical squamous intraepithelial lesions (SIL) classified as low grade (LSIL) or high grade (HSIL) in severity, which may progress to cervical cancer (21, 32, 47) . Human immunodeficiency virus (HIV) infection is associated with a higher prevalence of HPV, a higher incidence of SIL, and an increased risk for cervical cancer (1, 7, 9, 13, 15, 18, 19, 28-30, 33, 34, 38, 39) . Several studies of HIV-negative patients have indicated that higher HPV DNA loads in cervical scrapes are predictive of the severity of the underlying cervical lesion (3, 11, 16, 41, 42) . HPV16 viral loads were shown to be positively correlated with the risk for developing cervical carcinoma in situ (23, 46) . This could not be confirmed by Lorincz et al. when measuring cumulative loads of high-risk HPV types by Hybrid Capture without normalization on input cells (26) .
We designed type-specific real-time PCR protocols for the quantification of the commonest high-risk HPV types (HPV16, -18, -31, -33, -45, and -56), which prevail in more than 80% of cervical cancers worldwide (5, 44) . To evaluate the influence of HIV infection on HPV DNA load, we comparatively analyzed 305 cervical scrapes of HIV-positive and HIV-negative women with defined cervical disease stages (Table 1) . All patients had a complete gynecologic examination. Cervical scrapes for cytology and HPV load determination were taken by one investigator (A.M.F.). Colposcopy was performed on the patients' first visit and at following visits if the first cytology had been above normal. For HIV-positive patients, the number of CD4 cells per microliter, the HIV type 1 RNA load in plasma (Cobas Amplicor HIV-1 Monitor 1.5; Roche, Mannheim, Germany), and Centers for Disease Control and Prevention stage (8) were determined. DNA isolation from cervical scrapes (QIAamp-DNA Mini-Kit; Qiagen, Hilden, Germany), ␤-globin gene PCR (2), HPV screening-PCR (45) , and HPV typing (22) were performed as previously described. Sample characteristics and HPV DNA prevalence data are given in Table 1 . Quantification of HPV DNA was performed with the LightCycler (Roche) system as described before (45), with addition of 5% dimethyl sulfoxide to the PCR buffer. Sequences of type-specific primers and probes as well as PCR parameters are given in Table 2 . HPV DNA copy numbers were determined in duplicate by using standard curves, generated in the same PCR run with HPV-plasmid dilutions in a human placental DNA solution (40 ng/l) (4, 6, 12, 25, 31, 37) . Sensitivity was 5 to 10 copies of HPV DNA. Quantification was linear from 10 to 10 9 copies for all HPV types. Type specificity could be shown by testing 500,000 copies of heterologous HPV types (HPV6, -11, -16, -18, -31, -33, -45, and -56) instead of the target type, which never yielded signals above background. Reliability of quantification in the presence of other HPV types was tested by spiking six identical samples containing 1,000 copies of the target HPV type with 100,000 copies of frequent genital HPV types (HPV6, -11, -16, -18, -31, -33, -45, and -56), respectively. The test was designated reliable when spiked samples yielded copy numbers within the threefold standard deviation of six unspiked samples. To correct for PCR efficiency and DNA integrity and to determine the number of input cell equivalents, the single-copy-number gene ␤-globin was quantified by using the LightCycler Control Kit DNA (Roche). HPV DNA load was defined as the number of HPV DNA copies/␤-globin gene copy. Statistical analyses (17) were performed with SPSS 10.0.7 (SPSS Inc., Chicago, Ill.). Odds ratios (OR), 95% confidence intervals (CI), Fisher's exact tests, and Mann-Whitney U tests were based only on one sample per patient (the first HPV-positive sample collected).
We observed an increase of median HPV16 load with the severity of cervical disease in HIV-negative and HIV-positive patients (normal cytology for HIV-negative patients/HIV-positive patients, Ͻ0.1/Ͻ0.1; LSIL, 0.6/1.3; and HSIL, 14.6/63.2). For each cytological grade, strong load variations were ob-served. We, like others (41, 46), were therefore not able to define a clear cutoff predictive of HSIL. However, HPV16 loads that were Ͼ 1 were significantly associated with HSIL for HIV-negative (P Ͻ 0.001, OR, 8.3; CI, 2.8 to 24.5; and n ϭ 76) and HIV-positive (P Ͻ 0.001, OR, 41.2; CI, 2.1 to 778.7; and n ϭ 31) patients. In four scrapes from patients with cervical cancers, HPV DNA loads were above 1. The distribution of HPV16 loads in non-HSIL and HSIL scrapes is shown in Fig.  1 (non-HSIL includes normal cytology, atypical squamous cells of undetermined significance [ASCUS] , and LSIL). Graphs for non-HSIL scrapes of HIV-negative and HIV-positive patients are almost identical. For HPV18, -31, -33, -45, and -56 as well, no remarkable load differences could be seen in non-HSIL scrapes of HIV-negative and HIV-positive patients. In contrast, HPV16 loads were significantly higher in HSIL scrapes from HIV-positive patients than in those from HIV-negative patients (P ϭ 0.041; HIV ϩ n ϭ 14; and HIV Ϫ n ϭ 37) (Fig. 1) . The same tendency was seen for HPV18, -31, -45, and -56 but not for HPV33 (Table 3) . For patients in whom more than one sample was collected, the time interval between sample collections was 6 to 12 months. b fw, forward primer; bw, backward primer; So1, 5Ј hybridization probe (3Ј end labeled with fluorescein); So2, 3Ј hybridization probe (5Ј end labeled with LightCycler-Red-640 and 3Ј end phosphorylated).
c Primers used were at 0.5 M; hybridization probes were at 0.15 M.
In patients infected with more than one of the investigated six high-risk types, viral loads of individual types varied by up to 3 orders of magnitude. Interestingly, median HPV16 loads found in HSIL lesions infected with more than one HPV type were twofold (HIV positive: 72.8 versus 35.0; n ϭ 32) and fourfold (HIV negative: 23.7 versus 6.7; n ϭ 42) higher than those in HSIL lesions infected with HPV16 alone.
Stratification by CD4 cell count, AIDS status, and HIV RNA loads (Table 4) revealed that severe immunosuppression or high HIV RNA levels were generally associated with increased HPV loads in HSIL patients. These results extend preliminary data by Heard et al. (20) , who have found large HPV DNA amounts more frequently in severely immunosuppressed HIV-positive patients when comparing results from differently sensitive Southern blot and PCR analyses.
Elevated HPV DNA loads found in HIV-positive patients with HSIL could result from a higher proportion of infected cells shed from larger lesions and/or from enhanced HPV replication. The impaired immunity in HIV-positive patients will lead to a less efficient elimination of HPV-infected keratinocytes (10, 36) and thus to an expansion of lesions. Increased HPV DNA replication could be the consequence of direct or indirect effects of HIV (14, 43) , of synergistic effects of infections with multiple HPV types (see above), or of coinfections with other sexually transmitted agents, such as herpes simplex viruses (35) . An increased risk of malignant conversion can be expected both from the larger pool of HPV-infected cells in expanded lesions and from elevated gene doses, leading to higher concentrations of viral oncoproteins. All these mechanisms could contribute to the more aggressive course of cer-FIG. 1. Cumulative relative frequency of HPV16 DNA loads in cervical scrapes of HIV-negative and HIV-positive patients. Filled circles, HIV positive, non-HSIL (normal cytology, n ϭ 12; ASCUS, n ϭ 1; and LSIL, n ϭ 10); empty circles, HIV negative, non-HSIL (normal, n ϭ 24; ASCUS, n ϭ 8; LSIL, n ϭ 10); filled squares, HIV positive, HSIL (n ϭ 27); and empty squares, HIV negative, HSIL (n ϭ 40). HPV16 DNA loads above 300, which were only found in HSIL patients, are not shown (HIV ϩ , n ϭ 5; and HIV Ϫ , n ϭ 2). 
